[GetPortalCommentsPageByObjectIdResponse(id=2222724, encodeId=f35e2222e24b7, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:生殖内分泌<br>经验分享:朋友们,此期刊会进预警吗,浙大已经把frontiers全挂进预警了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c8b85315215, createdName=148975dam71暂无昵称, createdTime=Tue Aug 27 21:33:27 CST 2024, time=2024-08-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2109972, encodeId=b8e921099e22f, content=目前只有两个审稿人审稿,建议接受。现在状态变成The Associate Editor XX is evaluating any revisions made to the manuscript to take a final decision.<br>请问各位大佬还会继续邀请审稿人吗?这个状态会持续多久呀?谢谢你们<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1528458531, createdName=ms5000001329361729, createdTime=Thu Jan 12 16:16:25 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0<br>偏重的研究方向:糖尿病<br>经验分享:为什么我先被接受了,钱都交了,然后被拒了啊…………
This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208458, encodeId=124522084581c, content=请问这个期刊申请减免版面费的话成功率高么?会不会影响文章录用?通常文章什么状态的时候申请?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=我要毕业2024, createdTime=Wed Jun 05 15:54:27 CST 2024, time=2024-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198626, encodeId=15f5219862674, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:生殖医学<br>经验分享:15 Apr 2024 Article accepted for publication.<br>10 Apr 2024 Review of Review Editor 3 finalized.<br>04 Apr 2024 You posted new comments. Reviewer 3 posted new comments.<br>28 Mar 2024 Corresponding Author Chen Wang re-submitted manuscript.<br>14 Mar 2024 Interactive review forum activated.<br>25 Jan 2024 Review of Reviewer 1 is finalized.<br>23 Nov 2023 Corresponding Author Chen Wang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed3c2532598, createdName=125051b5m55(暂无昵称), createdTime=Mon Apr 15 15:36:02 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2165820, encodeId=716c2165820b0, content=感觉最近有点慢啊,卡在Editorial Assignment半个月了,丝毫没有动静,编辑们都去休假了吗?也还没到圣诞节吧..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230220/b6e40eea2fa5422ea67ef0e7c3b2e44b/808d8afa8f4d42fea20d07f572948bcf.jpg, createdBy=f8553109256, createdName=791313987, createdTime=Mon Oct 30 23:31:00 CST 2023, time=2023-10-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2179419, encodeId=74f721e94197a, content=偏重的研究方向:甲状腺癌<br>经验分享:现在cancer endocrinology板块的编辑是不是很忙,俩礼拜了还没分配编辑,还是内容不好,所以没有编辑愿意接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230712/7b1f2dc9a324479e9877047bc3d85ecd/b95cd487c3e24b4d8bfa2fc6ab30880c.jpg, createdBy=aed48754576, createdName=发大文章带我一个二十作吧, createdTime=Fri Jan 05 14:38:11 CST 2024, time=2024-01-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2131250, encodeId=976c213125070, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向:内分泌<br>经验分享:本人作为客座编辑在frontiers endocrinology(IF6.0)期刊开了一个主题为“Dysregulation of Metabolism and Associated Genes in Tumor Initiation, Development and Resistance to Radiotherapy and Immunotherapy”的专刊,现在已经开放投稿。如果大家有主题相关的稿件,欢迎大家积极投稿。投稿完成后,我会第一时间处理稿件并择优选择你们投稿时推荐的审稿专家,提升稿件处理流程和接收速度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 22:48:06 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2167281, encodeId=c94f216e28178, content=偏重的研究方向:癌症;Endocrinology<br>经验分享:投稿花了一个多月分配编辑,分配后邀请两个审稿人提交报告1个月,然后一直没动静,等了一个多月没有变化。这期刊也太不靠谱了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65ab5425857, createdName=Doctorfan, createdTime=Tue Nov 07 22:03:52 CST 2023, time=2023-11-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2108928, encodeId=aef1210892807, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向:糖尿病并发症<br>经验分享:给大家分享我的投稿经历,综述文章(也是从别的杂志转投过来的),找审稿人用了很长时间,期间还发邮件让我推荐最多十位审稿人,最终我的文章找到三个审稿人(有一人退出审稿),两个审稿人(Reviewer1有5个问题,Reviewer3有8个问题)提的问题自认为并不复杂,基本是语言需要润色,表格需要合并,摘要和讨论部分需要精细一下等。给了一周时间修改,我进行润色并仔细回答问题,11月14号按时投回。之前投内分泌前言的经验是投回很快就告诉接收。结果我等到12月27号收到拒稿,理由是This manuscript does not fulfill the standards established for the journal to be considered for publication. The overall judgement of the reviewers and handling editor is that the authors couldn't satisfy the concerns after during the review process. also, A lack of novelty exists.我就想说,你的理由真是服,送审之前想什么呢?将近4个月时间打水漂。。。。。。好在我没那么着急用它。而且我之前另一篇文章投过一次这个杂志,也是经历和这次一模一样,由于不服气申诉了,后来重新审稿最终接收。这次被拒不想在申诉了,也心累,可能是因为人家升区了吧。<br>27 Dec 2022 Article rejected by Specialty Chief<br>22 Nov 2022 Review of Review Editor 1 finalized<br>21 Nov 2022 Review of Review Editor 3 finalized<br>14 Nov 2022 <br>Review of Review Editor 1 finalized<br>Corresponding Author re-submitted manuscript<br>You posted new comments<br>07 Nov 2022 <br>Interactive review forum activated<br>Review of Reviewer 3 is finalized<br>06 Sep 2022 Manuscript transferred to Frontiers in Endocrinology, section Cellular Endocrinology, research topic: None, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210722/ce07e4a5c3c140a6bb8f19209b4271a4/4355f14397864d6c8f0343fc06a29351.jpg, createdBy=614c5554341, createdName=ms1000000414896070, createdTime=Thu Jan 05 13:58:40 CST 2023, time=2023-01-05, status=1, ipAttribution=吉林省)]
[GetPortalCommentsPageByObjectIdResponse(id=2222724, encodeId=f35e2222e24b7, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:生殖内分泌<br>经验分享:朋友们,此期刊会进预警吗,浙大已经把frontiers全挂进预警了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c8b85315215, createdName=148975dam71暂无昵称, createdTime=Tue Aug 27 21:33:27 CST 2024, time=2024-08-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2109972, encodeId=b8e921099e22f, content=目前只有两个审稿人审稿,建议接受。现在状态变成The Associate Editor XX is evaluating any revisions made to the manuscript to take a final decision.<br>请问各位大佬还会继续邀请审稿人吗?这个状态会持续多久呀?谢谢你们<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1528458531, createdName=ms5000001329361729, createdTime=Thu Jan 12 16:16:25 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0<br>偏重的研究方向:糖尿病<br>经验分享:为什么我先被接受了,钱都交了,然后被拒了啊…………
This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208458, encodeId=124522084581c, content=请问这个期刊申请减免版面费的话成功率高么?会不会影响文章录用?通常文章什么状态的时候申请?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=我要毕业2024, createdTime=Wed Jun 05 15:54:27 CST 2024, time=2024-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198626, encodeId=15f5219862674, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:生殖医学<br>经验分享:15 Apr 2024 Article accepted for publication.<br>10 Apr 2024 Review of Review Editor 3 finalized.<br>04 Apr 2024 You posted new comments. Reviewer 3 posted new comments.<br>28 Mar 2024 Corresponding Author Chen Wang re-submitted manuscript.<br>14 Mar 2024 Interactive review forum activated.<br>25 Jan 2024 Review of Reviewer 1 is finalized.<br>23 Nov 2023 Corresponding Author Chen Wang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed3c2532598, createdName=125051b5m55(暂无昵称), createdTime=Mon Apr 15 15:36:02 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2165820, encodeId=716c2165820b0, content=感觉最近有点慢啊,卡在Editorial Assignment半个月了,丝毫没有动静,编辑们都去休假了吗?也还没到圣诞节吧..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230220/b6e40eea2fa5422ea67ef0e7c3b2e44b/808d8afa8f4d42fea20d07f572948bcf.jpg, createdBy=f8553109256, createdName=791313987, createdTime=Mon Oct 30 23:31:00 CST 2023, time=2023-10-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2179419, encodeId=74f721e94197a, content=偏重的研究方向:甲状腺癌<br>经验分享:现在cancer endocrinology板块的编辑是不是很忙,俩礼拜了还没分配编辑,还是内容不好,所以没有编辑愿意接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230712/7b1f2dc9a324479e9877047bc3d85ecd/b95cd487c3e24b4d8bfa2fc6ab30880c.jpg, createdBy=aed48754576, createdName=发大文章带我一个二十作吧, createdTime=Fri Jan 05 14:38:11 CST 2024, time=2024-01-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2131250, encodeId=976c213125070, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向:内分泌<br>经验分享:本人作为客座编辑在frontiers endocrinology(IF6.0)期刊开了一个主题为“Dysregulation of Metabolism and Associated Genes in Tumor Initiation, Development and Resistance to Radiotherapy and Immunotherapy”的专刊,现在已经开放投稿。如果大家有主题相关的稿件,欢迎大家积极投稿。投稿完成后,我会第一时间处理稿件并择优选择你们投稿时推荐的审稿专家,提升稿件处理流程和接收速度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 22:48:06 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2167281, encodeId=c94f216e28178, content=偏重的研究方向:癌症;Endocrinology<br>经验分享:投稿花了一个多月分配编辑,分配后邀请两个审稿人提交报告1个月,然后一直没动静,等了一个多月没有变化。这期刊也太不靠谱了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65ab5425857, createdName=Doctorfan, createdTime=Tue Nov 07 22:03:52 CST 2023, time=2023-11-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2108928, encodeId=aef1210892807, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向:糖尿病并发症<br>经验分享:给大家分享我的投稿经历,综述文章(也是从别的杂志转投过来的),找审稿人用了很长时间,期间还发邮件让我推荐最多十位审稿人,最终我的文章找到三个审稿人(有一人退出审稿),两个审稿人(Reviewer1有5个问题,Reviewer3有8个问题)提的问题自认为并不复杂,基本是语言需要润色,表格需要合并,摘要和讨论部分需要精细一下等。给了一周时间修改,我进行润色并仔细回答问题,11月14号按时投回。之前投内分泌前言的经验是投回很快就告诉接收。结果我等到12月27号收到拒稿,理由是This manuscript does not fulfill the standards established for the journal to be considered for publication. The overall judgement of the reviewers and handling editor is that the authors couldn't satisfy the concerns after during the review process. also, A lack of novelty exists.我就想说,你的理由真是服,送审之前想什么呢?将近4个月时间打水漂。。。。。。好在我没那么着急用它。而且我之前另一篇文章投过一次这个杂志,也是经历和这次一模一样,由于不服气申诉了,后来重新审稿最终接收。这次被拒不想在申诉了,也心累,可能是因为人家升区了吧。<br>27 Dec 2022 Article rejected by Specialty Chief<br>22 Nov 2022 Review of Review Editor 1 finalized<br>21 Nov 2022 Review of Review Editor 3 finalized<br>14 Nov 2022 <br>Review of Review Editor 1 finalized<br>Corresponding Author re-submitted manuscript<br>You posted new comments<br>07 Nov 2022 <br>Interactive review forum activated<br>Review of Reviewer 3 is finalized<br>06 Sep 2022 Manuscript transferred to Frontiers in Endocrinology, section Cellular Endocrinology, research topic: None, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210722/ce07e4a5c3c140a6bb8f19209b4271a4/4355f14397864d6c8f0343fc06a29351.jpg, createdBy=614c5554341, createdName=ms1000000414896070, createdTime=Thu Jan 05 13:58:40 CST 2023, time=2023-01-05, status=1, ipAttribution=吉林省)]
目前只有两个审稿人审稿,建议接受。现在状态变成The Associate Editor XX is evaluating any revisions made to the manuscript to take a final decision. 请问各位大佬还会继续邀请审稿人吗?这个状态会持续多久呀?谢谢你们
[GetPortalCommentsPageByObjectIdResponse(id=2222724, encodeId=f35e2222e24b7, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:生殖内分泌<br>经验分享:朋友们,此期刊会进预警吗,浙大已经把frontiers全挂进预警了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c8b85315215, createdName=148975dam71暂无昵称, createdTime=Tue Aug 27 21:33:27 CST 2024, time=2024-08-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2109972, encodeId=b8e921099e22f, content=目前只有两个审稿人审稿,建议接受。现在状态变成The Associate Editor XX is evaluating any revisions made to the manuscript to take a final decision.<br>请问各位大佬还会继续邀请审稿人吗?这个状态会持续多久呀?谢谢你们<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1528458531, createdName=ms5000001329361729, createdTime=Thu Jan 12 16:16:25 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0<br>偏重的研究方向:糖尿病<br>经验分享:为什么我先被接受了,钱都交了,然后被拒了啊…………
This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208458, encodeId=124522084581c, content=请问这个期刊申请减免版面费的话成功率高么?会不会影响文章录用?通常文章什么状态的时候申请?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=我要毕业2024, createdTime=Wed Jun 05 15:54:27 CST 2024, time=2024-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198626, encodeId=15f5219862674, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:生殖医学<br>经验分享:15 Apr 2024 Article accepted for publication.<br>10 Apr 2024 Review of Review Editor 3 finalized.<br>04 Apr 2024 You posted new comments. Reviewer 3 posted new comments.<br>28 Mar 2024 Corresponding Author Chen Wang re-submitted manuscript.<br>14 Mar 2024 Interactive review forum activated.<br>25 Jan 2024 Review of Reviewer 1 is finalized.<br>23 Nov 2023 Corresponding Author Chen Wang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed3c2532598, createdName=125051b5m55(暂无昵称), createdTime=Mon Apr 15 15:36:02 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2165820, encodeId=716c2165820b0, content=感觉最近有点慢啊,卡在Editorial Assignment半个月了,丝毫没有动静,编辑们都去休假了吗?也还没到圣诞节吧..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230220/b6e40eea2fa5422ea67ef0e7c3b2e44b/808d8afa8f4d42fea20d07f572948bcf.jpg, createdBy=f8553109256, createdName=791313987, createdTime=Mon Oct 30 23:31:00 CST 2023, time=2023-10-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2179419, encodeId=74f721e94197a, content=偏重的研究方向:甲状腺癌<br>经验分享:现在cancer endocrinology板块的编辑是不是很忙,俩礼拜了还没分配编辑,还是内容不好,所以没有编辑愿意接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230712/7b1f2dc9a324479e9877047bc3d85ecd/b95cd487c3e24b4d8bfa2fc6ab30880c.jpg, createdBy=aed48754576, createdName=发大文章带我一个二十作吧, createdTime=Fri Jan 05 14:38:11 CST 2024, time=2024-01-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2131250, encodeId=976c213125070, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向:内分泌<br>经验分享:本人作为客座编辑在frontiers endocrinology(IF6.0)期刊开了一个主题为“Dysregulation of Metabolism and Associated Genes in Tumor Initiation, Development and Resistance to Radiotherapy and Immunotherapy”的专刊,现在已经开放投稿。如果大家有主题相关的稿件,欢迎大家积极投稿。投稿完成后,我会第一时间处理稿件并择优选择你们投稿时推荐的审稿专家,提升稿件处理流程和接收速度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 22:48:06 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2167281, encodeId=c94f216e28178, content=偏重的研究方向:癌症;Endocrinology<br>经验分享:投稿花了一个多月分配编辑,分配后邀请两个审稿人提交报告1个月,然后一直没动静,等了一个多月没有变化。这期刊也太不靠谱了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65ab5425857, createdName=Doctorfan, createdTime=Tue Nov 07 22:03:52 CST 2023, time=2023-11-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2108928, encodeId=aef1210892807, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向:糖尿病并发症<br>经验分享:给大家分享我的投稿经历,综述文章(也是从别的杂志转投过来的),找审稿人用了很长时间,期间还发邮件让我推荐最多十位审稿人,最终我的文章找到三个审稿人(有一人退出审稿),两个审稿人(Reviewer1有5个问题,Reviewer3有8个问题)提的问题自认为并不复杂,基本是语言需要润色,表格需要合并,摘要和讨论部分需要精细一下等。给了一周时间修改,我进行润色并仔细回答问题,11月14号按时投回。之前投内分泌前言的经验是投回很快就告诉接收。结果我等到12月27号收到拒稿,理由是This manuscript does not fulfill the standards established for the journal to be considered for publication. The overall judgement of the reviewers and handling editor is that the authors couldn't satisfy the concerns after during the review process. also, A lack of novelty exists.我就想说,你的理由真是服,送审之前想什么呢?将近4个月时间打水漂。。。。。。好在我没那么着急用它。而且我之前另一篇文章投过一次这个杂志,也是经历和这次一模一样,由于不服气申诉了,后来重新审稿最终接收。这次被拒不想在申诉了,也心累,可能是因为人家升区了吧。<br>27 Dec 2022 Article rejected by Specialty Chief<br>22 Nov 2022 Review of Review Editor 1 finalized<br>21 Nov 2022 Review of Review Editor 3 finalized<br>14 Nov 2022 <br>Review of Review Editor 1 finalized<br>Corresponding Author re-submitted manuscript<br>You posted new comments<br>07 Nov 2022 <br>Interactive review forum activated<br>Review of Reviewer 3 is finalized<br>06 Sep 2022 Manuscript transferred to Frontiers in Endocrinology, section Cellular Endocrinology, research topic: None, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210722/ce07e4a5c3c140a6bb8f19209b4271a4/4355f14397864d6c8f0343fc06a29351.jpg, createdBy=614c5554341, createdName=ms1000000414896070, createdTime=Thu Jan 05 13:58:40 CST 2023, time=2023-01-05, status=1, ipAttribution=吉林省)]
审稿速度:1.0 偏重的研究方向:糖尿病 经验分享:为什么我先被接受了,钱都交了,然后被拒了啊…………
This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final.
[GetPortalCommentsPageByObjectIdResponse(id=2222724, encodeId=f35e2222e24b7, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:生殖内分泌<br>经验分享:朋友们,此期刊会进预警吗,浙大已经把frontiers全挂进预警了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c8b85315215, createdName=148975dam71暂无昵称, createdTime=Tue Aug 27 21:33:27 CST 2024, time=2024-08-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2109972, encodeId=b8e921099e22f, content=目前只有两个审稿人审稿,建议接受。现在状态变成The Associate Editor XX is evaluating any revisions made to the manuscript to take a final decision.<br>请问各位大佬还会继续邀请审稿人吗?这个状态会持续多久呀?谢谢你们<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1528458531, createdName=ms5000001329361729, createdTime=Thu Jan 12 16:16:25 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0<br>偏重的研究方向:糖尿病<br>经验分享:为什么我先被接受了,钱都交了,然后被拒了啊…………
This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208458, encodeId=124522084581c, content=请问这个期刊申请减免版面费的话成功率高么?会不会影响文章录用?通常文章什么状态的时候申请?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=我要毕业2024, createdTime=Wed Jun 05 15:54:27 CST 2024, time=2024-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198626, encodeId=15f5219862674, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:生殖医学<br>经验分享:15 Apr 2024 Article accepted for publication.<br>10 Apr 2024 Review of Review Editor 3 finalized.<br>04 Apr 2024 You posted new comments. Reviewer 3 posted new comments.<br>28 Mar 2024 Corresponding Author Chen Wang re-submitted manuscript.<br>14 Mar 2024 Interactive review forum activated.<br>25 Jan 2024 Review of Reviewer 1 is finalized.<br>23 Nov 2023 Corresponding Author Chen Wang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed3c2532598, createdName=125051b5m55(暂无昵称), createdTime=Mon Apr 15 15:36:02 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2165820, encodeId=716c2165820b0, content=感觉最近有点慢啊,卡在Editorial Assignment半个月了,丝毫没有动静,编辑们都去休假了吗?也还没到圣诞节吧..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230220/b6e40eea2fa5422ea67ef0e7c3b2e44b/808d8afa8f4d42fea20d07f572948bcf.jpg, createdBy=f8553109256, createdName=791313987, createdTime=Mon Oct 30 23:31:00 CST 2023, time=2023-10-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2179419, encodeId=74f721e94197a, content=偏重的研究方向:甲状腺癌<br>经验分享:现在cancer endocrinology板块的编辑是不是很忙,俩礼拜了还没分配编辑,还是内容不好,所以没有编辑愿意接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230712/7b1f2dc9a324479e9877047bc3d85ecd/b95cd487c3e24b4d8bfa2fc6ab30880c.jpg, createdBy=aed48754576, createdName=发大文章带我一个二十作吧, createdTime=Fri Jan 05 14:38:11 CST 2024, time=2024-01-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2131250, encodeId=976c213125070, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向:内分泌<br>经验分享:本人作为客座编辑在frontiers endocrinology(IF6.0)期刊开了一个主题为“Dysregulation of Metabolism and Associated Genes in Tumor Initiation, Development and Resistance to Radiotherapy and Immunotherapy”的专刊,现在已经开放投稿。如果大家有主题相关的稿件,欢迎大家积极投稿。投稿完成后,我会第一时间处理稿件并择优选择你们投稿时推荐的审稿专家,提升稿件处理流程和接收速度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 22:48:06 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2167281, encodeId=c94f216e28178, content=偏重的研究方向:癌症;Endocrinology<br>经验分享:投稿花了一个多月分配编辑,分配后邀请两个审稿人提交报告1个月,然后一直没动静,等了一个多月没有变化。这期刊也太不靠谱了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65ab5425857, createdName=Doctorfan, createdTime=Tue Nov 07 22:03:52 CST 2023, time=2023-11-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2108928, encodeId=aef1210892807, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向:糖尿病并发症<br>经验分享:给大家分享我的投稿经历,综述文章(也是从别的杂志转投过来的),找审稿人用了很长时间,期间还发邮件让我推荐最多十位审稿人,最终我的文章找到三个审稿人(有一人退出审稿),两个审稿人(Reviewer1有5个问题,Reviewer3有8个问题)提的问题自认为并不复杂,基本是语言需要润色,表格需要合并,摘要和讨论部分需要精细一下等。给了一周时间修改,我进行润色并仔细回答问题,11月14号按时投回。之前投内分泌前言的经验是投回很快就告诉接收。结果我等到12月27号收到拒稿,理由是This manuscript does not fulfill the standards established for the journal to be considered for publication. The overall judgement of the reviewers and handling editor is that the authors couldn't satisfy the concerns after during the review process. also, A lack of novelty exists.我就想说,你的理由真是服,送审之前想什么呢?将近4个月时间打水漂。。。。。。好在我没那么着急用它。而且我之前另一篇文章投过一次这个杂志,也是经历和这次一模一样,由于不服气申诉了,后来重新审稿最终接收。这次被拒不想在申诉了,也心累,可能是因为人家升区了吧。<br>27 Dec 2022 Article rejected by Specialty Chief<br>22 Nov 2022 Review of Review Editor 1 finalized<br>21 Nov 2022 Review of Review Editor 3 finalized<br>14 Nov 2022 <br>Review of Review Editor 1 finalized<br>Corresponding Author re-submitted manuscript<br>You posted new comments<br>07 Nov 2022 <br>Interactive review forum activated<br>Review of Reviewer 3 is finalized<br>06 Sep 2022 Manuscript transferred to Frontiers in Endocrinology, section Cellular Endocrinology, research topic: None, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210722/ce07e4a5c3c140a6bb8f19209b4271a4/4355f14397864d6c8f0343fc06a29351.jpg, createdBy=614c5554341, createdName=ms1000000414896070, createdTime=Thu Jan 05 13:58:40 CST 2023, time=2023-01-05, status=1, ipAttribution=吉林省)]
[GetPortalCommentsPageByObjectIdResponse(id=2222724, encodeId=f35e2222e24b7, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:生殖内分泌<br>经验分享:朋友们,此期刊会进预警吗,浙大已经把frontiers全挂进预警了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c8b85315215, createdName=148975dam71暂无昵称, createdTime=Tue Aug 27 21:33:27 CST 2024, time=2024-08-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2109972, encodeId=b8e921099e22f, content=目前只有两个审稿人审稿,建议接受。现在状态变成The Associate Editor XX is evaluating any revisions made to the manuscript to take a final decision.<br>请问各位大佬还会继续邀请审稿人吗?这个状态会持续多久呀?谢谢你们<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1528458531, createdName=ms5000001329361729, createdTime=Thu Jan 12 16:16:25 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0<br>偏重的研究方向:糖尿病<br>经验分享:为什么我先被接受了,钱都交了,然后被拒了啊…………
This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208458, encodeId=124522084581c, content=请问这个期刊申请减免版面费的话成功率高么?会不会影响文章录用?通常文章什么状态的时候申请?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=我要毕业2024, createdTime=Wed Jun 05 15:54:27 CST 2024, time=2024-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198626, encodeId=15f5219862674, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:生殖医学<br>经验分享:15 Apr 2024 Article accepted for publication.<br>10 Apr 2024 Review of Review Editor 3 finalized.<br>04 Apr 2024 You posted new comments. Reviewer 3 posted new comments.<br>28 Mar 2024 Corresponding Author Chen Wang re-submitted manuscript.<br>14 Mar 2024 Interactive review forum activated.<br>25 Jan 2024 Review of Reviewer 1 is finalized.<br>23 Nov 2023 Corresponding Author Chen Wang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed3c2532598, createdName=125051b5m55(暂无昵称), createdTime=Mon Apr 15 15:36:02 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2165820, encodeId=716c2165820b0, content=感觉最近有点慢啊,卡在Editorial Assignment半个月了,丝毫没有动静,编辑们都去休假了吗?也还没到圣诞节吧..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230220/b6e40eea2fa5422ea67ef0e7c3b2e44b/808d8afa8f4d42fea20d07f572948bcf.jpg, createdBy=f8553109256, createdName=791313987, createdTime=Mon Oct 30 23:31:00 CST 2023, time=2023-10-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2179419, encodeId=74f721e94197a, content=偏重的研究方向:甲状腺癌<br>经验分享:现在cancer endocrinology板块的编辑是不是很忙,俩礼拜了还没分配编辑,还是内容不好,所以没有编辑愿意接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230712/7b1f2dc9a324479e9877047bc3d85ecd/b95cd487c3e24b4d8bfa2fc6ab30880c.jpg, createdBy=aed48754576, createdName=发大文章带我一个二十作吧, createdTime=Fri Jan 05 14:38:11 CST 2024, time=2024-01-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2131250, encodeId=976c213125070, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向:内分泌<br>经验分享:本人作为客座编辑在frontiers endocrinology(IF6.0)期刊开了一个主题为“Dysregulation of Metabolism and Associated Genes in Tumor Initiation, Development and Resistance to Radiotherapy and Immunotherapy”的专刊,现在已经开放投稿。如果大家有主题相关的稿件,欢迎大家积极投稿。投稿完成后,我会第一时间处理稿件并择优选择你们投稿时推荐的审稿专家,提升稿件处理流程和接收速度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 22:48:06 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2167281, encodeId=c94f216e28178, content=偏重的研究方向:癌症;Endocrinology<br>经验分享:投稿花了一个多月分配编辑,分配后邀请两个审稿人提交报告1个月,然后一直没动静,等了一个多月没有变化。这期刊也太不靠谱了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65ab5425857, createdName=Doctorfan, createdTime=Tue Nov 07 22:03:52 CST 2023, time=2023-11-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2108928, encodeId=aef1210892807, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向:糖尿病并发症<br>经验分享:给大家分享我的投稿经历,综述文章(也是从别的杂志转投过来的),找审稿人用了很长时间,期间还发邮件让我推荐最多十位审稿人,最终我的文章找到三个审稿人(有一人退出审稿),两个审稿人(Reviewer1有5个问题,Reviewer3有8个问题)提的问题自认为并不复杂,基本是语言需要润色,表格需要合并,摘要和讨论部分需要精细一下等。给了一周时间修改,我进行润色并仔细回答问题,11月14号按时投回。之前投内分泌前言的经验是投回很快就告诉接收。结果我等到12月27号收到拒稿,理由是This manuscript does not fulfill the standards established for the journal to be considered for publication. The overall judgement of the reviewers and handling editor is that the authors couldn't satisfy the concerns after during the review process. also, A lack of novelty exists.我就想说,你的理由真是服,送审之前想什么呢?将近4个月时间打水漂。。。。。。好在我没那么着急用它。而且我之前另一篇文章投过一次这个杂志,也是经历和这次一模一样,由于不服气申诉了,后来重新审稿最终接收。这次被拒不想在申诉了,也心累,可能是因为人家升区了吧。<br>27 Dec 2022 Article rejected by Specialty Chief<br>22 Nov 2022 Review of Review Editor 1 finalized<br>21 Nov 2022 Review of Review Editor 3 finalized<br>14 Nov 2022 <br>Review of Review Editor 1 finalized<br>Corresponding Author re-submitted manuscript<br>You posted new comments<br>07 Nov 2022 <br>Interactive review forum activated<br>Review of Reviewer 3 is finalized<br>06 Sep 2022 Manuscript transferred to Frontiers in Endocrinology, section Cellular Endocrinology, research topic: None, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210722/ce07e4a5c3c140a6bb8f19209b4271a4/4355f14397864d6c8f0343fc06a29351.jpg, createdBy=614c5554341, createdName=ms1000000414896070, createdTime=Thu Jan 05 13:58:40 CST 2023, time=2023-01-05, status=1, ipAttribution=吉林省)]
审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向:生殖医学 经验分享:15 Apr 2024 Article accepted for publication. 10 Apr 2024 Review of Review Editor 3 finalized. 04 Apr 2024 You posted new comments. Reviewer 3 posted new comments. 28 Mar 2024 Corresponding Author Chen Wang re-submitted manuscript. 14 Mar 2024 Interactive review forum activated. 25 Jan 2024 Review of Reviewer 1 is finalized. 23 Nov 2023 Corresponding Author Chen Wang submitted manuscript.
[GetPortalCommentsPageByObjectIdResponse(id=2222724, encodeId=f35e2222e24b7, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:生殖内分泌<br>经验分享:朋友们,此期刊会进预警吗,浙大已经把frontiers全挂进预警了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c8b85315215, createdName=148975dam71暂无昵称, createdTime=Tue Aug 27 21:33:27 CST 2024, time=2024-08-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2109972, encodeId=b8e921099e22f, content=目前只有两个审稿人审稿,建议接受。现在状态变成The Associate Editor XX is evaluating any revisions made to the manuscript to take a final decision.<br>请问各位大佬还会继续邀请审稿人吗?这个状态会持续多久呀?谢谢你们<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1528458531, createdName=ms5000001329361729, createdTime=Thu Jan 12 16:16:25 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0<br>偏重的研究方向:糖尿病<br>经验分享:为什么我先被接受了,钱都交了,然后被拒了啊…………
This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208458, encodeId=124522084581c, content=请问这个期刊申请减免版面费的话成功率高么?会不会影响文章录用?通常文章什么状态的时候申请?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=我要毕业2024, createdTime=Wed Jun 05 15:54:27 CST 2024, time=2024-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198626, encodeId=15f5219862674, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:生殖医学<br>经验分享:15 Apr 2024 Article accepted for publication.<br>10 Apr 2024 Review of Review Editor 3 finalized.<br>04 Apr 2024 You posted new comments. Reviewer 3 posted new comments.<br>28 Mar 2024 Corresponding Author Chen Wang re-submitted manuscript.<br>14 Mar 2024 Interactive review forum activated.<br>25 Jan 2024 Review of Reviewer 1 is finalized.<br>23 Nov 2023 Corresponding Author Chen Wang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed3c2532598, createdName=125051b5m55(暂无昵称), createdTime=Mon Apr 15 15:36:02 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2165820, encodeId=716c2165820b0, content=感觉最近有点慢啊,卡在Editorial Assignment半个月了,丝毫没有动静,编辑们都去休假了吗?也还没到圣诞节吧..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230220/b6e40eea2fa5422ea67ef0e7c3b2e44b/808d8afa8f4d42fea20d07f572948bcf.jpg, createdBy=f8553109256, createdName=791313987, createdTime=Mon Oct 30 23:31:00 CST 2023, time=2023-10-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2179419, encodeId=74f721e94197a, content=偏重的研究方向:甲状腺癌<br>经验分享:现在cancer endocrinology板块的编辑是不是很忙,俩礼拜了还没分配编辑,还是内容不好,所以没有编辑愿意接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230712/7b1f2dc9a324479e9877047bc3d85ecd/b95cd487c3e24b4d8bfa2fc6ab30880c.jpg, createdBy=aed48754576, createdName=发大文章带我一个二十作吧, createdTime=Fri Jan 05 14:38:11 CST 2024, time=2024-01-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2131250, encodeId=976c213125070, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向:内分泌<br>经验分享:本人作为客座编辑在frontiers endocrinology(IF6.0)期刊开了一个主题为“Dysregulation of Metabolism and Associated Genes in Tumor Initiation, Development and Resistance to Radiotherapy and Immunotherapy”的专刊,现在已经开放投稿。如果大家有主题相关的稿件,欢迎大家积极投稿。投稿完成后,我会第一时间处理稿件并择优选择你们投稿时推荐的审稿专家,提升稿件处理流程和接收速度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 22:48:06 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2167281, encodeId=c94f216e28178, content=偏重的研究方向:癌症;Endocrinology<br>经验分享:投稿花了一个多月分配编辑,分配后邀请两个审稿人提交报告1个月,然后一直没动静,等了一个多月没有变化。这期刊也太不靠谱了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65ab5425857, createdName=Doctorfan, createdTime=Tue Nov 07 22:03:52 CST 2023, time=2023-11-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2108928, encodeId=aef1210892807, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向:糖尿病并发症<br>经验分享:给大家分享我的投稿经历,综述文章(也是从别的杂志转投过来的),找审稿人用了很长时间,期间还发邮件让我推荐最多十位审稿人,最终我的文章找到三个审稿人(有一人退出审稿),两个审稿人(Reviewer1有5个问题,Reviewer3有8个问题)提的问题自认为并不复杂,基本是语言需要润色,表格需要合并,摘要和讨论部分需要精细一下等。给了一周时间修改,我进行润色并仔细回答问题,11月14号按时投回。之前投内分泌前言的经验是投回很快就告诉接收。结果我等到12月27号收到拒稿,理由是This manuscript does not fulfill the standards established for the journal to be considered for publication. The overall judgement of the reviewers and handling editor is that the authors couldn't satisfy the concerns after during the review process. also, A lack of novelty exists.我就想说,你的理由真是服,送审之前想什么呢?将近4个月时间打水漂。。。。。。好在我没那么着急用它。而且我之前另一篇文章投过一次这个杂志,也是经历和这次一模一样,由于不服气申诉了,后来重新审稿最终接收。这次被拒不想在申诉了,也心累,可能是因为人家升区了吧。<br>27 Dec 2022 Article rejected by Specialty Chief<br>22 Nov 2022 Review of Review Editor 1 finalized<br>21 Nov 2022 Review of Review Editor 3 finalized<br>14 Nov 2022 <br>Review of Review Editor 1 finalized<br>Corresponding Author re-submitted manuscript<br>You posted new comments<br>07 Nov 2022 <br>Interactive review forum activated<br>Review of Reviewer 3 is finalized<br>06 Sep 2022 Manuscript transferred to Frontiers in Endocrinology, section Cellular Endocrinology, research topic: None, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210722/ce07e4a5c3c140a6bb8f19209b4271a4/4355f14397864d6c8f0343fc06a29351.jpg, createdBy=614c5554341, createdName=ms1000000414896070, createdTime=Thu Jan 05 13:58:40 CST 2023, time=2023-01-05, status=1, ipAttribution=吉林省)]
[GetPortalCommentsPageByObjectIdResponse(id=2222724, encodeId=f35e2222e24b7, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:生殖内分泌<br>经验分享:朋友们,此期刊会进预警吗,浙大已经把frontiers全挂进预警了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c8b85315215, createdName=148975dam71暂无昵称, createdTime=Tue Aug 27 21:33:27 CST 2024, time=2024-08-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2109972, encodeId=b8e921099e22f, content=目前只有两个审稿人审稿,建议接受。现在状态变成The Associate Editor XX is evaluating any revisions made to the manuscript to take a final decision.<br>请问各位大佬还会继续邀请审稿人吗?这个状态会持续多久呀?谢谢你们<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1528458531, createdName=ms5000001329361729, createdTime=Thu Jan 12 16:16:25 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0<br>偏重的研究方向:糖尿病<br>经验分享:为什么我先被接受了,钱都交了,然后被拒了啊…………
This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208458, encodeId=124522084581c, content=请问这个期刊申请减免版面费的话成功率高么?会不会影响文章录用?通常文章什么状态的时候申请?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=我要毕业2024, createdTime=Wed Jun 05 15:54:27 CST 2024, time=2024-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198626, encodeId=15f5219862674, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:生殖医学<br>经验分享:15 Apr 2024 Article accepted for publication.<br>10 Apr 2024 Review of Review Editor 3 finalized.<br>04 Apr 2024 You posted new comments. Reviewer 3 posted new comments.<br>28 Mar 2024 Corresponding Author Chen Wang re-submitted manuscript.<br>14 Mar 2024 Interactive review forum activated.<br>25 Jan 2024 Review of Reviewer 1 is finalized.<br>23 Nov 2023 Corresponding Author Chen Wang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed3c2532598, createdName=125051b5m55(暂无昵称), createdTime=Mon Apr 15 15:36:02 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2165820, encodeId=716c2165820b0, content=感觉最近有点慢啊,卡在Editorial Assignment半个月了,丝毫没有动静,编辑们都去休假了吗?也还没到圣诞节吧..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230220/b6e40eea2fa5422ea67ef0e7c3b2e44b/808d8afa8f4d42fea20d07f572948bcf.jpg, createdBy=f8553109256, createdName=791313987, createdTime=Mon Oct 30 23:31:00 CST 2023, time=2023-10-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2179419, encodeId=74f721e94197a, content=偏重的研究方向:甲状腺癌<br>经验分享:现在cancer endocrinology板块的编辑是不是很忙,俩礼拜了还没分配编辑,还是内容不好,所以没有编辑愿意接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230712/7b1f2dc9a324479e9877047bc3d85ecd/b95cd487c3e24b4d8bfa2fc6ab30880c.jpg, createdBy=aed48754576, createdName=发大文章带我一个二十作吧, createdTime=Fri Jan 05 14:38:11 CST 2024, time=2024-01-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2131250, encodeId=976c213125070, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向:内分泌<br>经验分享:本人作为客座编辑在frontiers endocrinology(IF6.0)期刊开了一个主题为“Dysregulation of Metabolism and Associated Genes in Tumor Initiation, Development and Resistance to Radiotherapy and Immunotherapy”的专刊,现在已经开放投稿。如果大家有主题相关的稿件,欢迎大家积极投稿。投稿完成后,我会第一时间处理稿件并择优选择你们投稿时推荐的审稿专家,提升稿件处理流程和接收速度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 22:48:06 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2167281, encodeId=c94f216e28178, content=偏重的研究方向:癌症;Endocrinology<br>经验分享:投稿花了一个多月分配编辑,分配后邀请两个审稿人提交报告1个月,然后一直没动静,等了一个多月没有变化。这期刊也太不靠谱了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65ab5425857, createdName=Doctorfan, createdTime=Tue Nov 07 22:03:52 CST 2023, time=2023-11-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2108928, encodeId=aef1210892807, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向:糖尿病并发症<br>经验分享:给大家分享我的投稿经历,综述文章(也是从别的杂志转投过来的),找审稿人用了很长时间,期间还发邮件让我推荐最多十位审稿人,最终我的文章找到三个审稿人(有一人退出审稿),两个审稿人(Reviewer1有5个问题,Reviewer3有8个问题)提的问题自认为并不复杂,基本是语言需要润色,表格需要合并,摘要和讨论部分需要精细一下等。给了一周时间修改,我进行润色并仔细回答问题,11月14号按时投回。之前投内分泌前言的经验是投回很快就告诉接收。结果我等到12月27号收到拒稿,理由是This manuscript does not fulfill the standards established for the journal to be considered for publication. The overall judgement of the reviewers and handling editor is that the authors couldn't satisfy the concerns after during the review process. also, A lack of novelty exists.我就想说,你的理由真是服,送审之前想什么呢?将近4个月时间打水漂。。。。。。好在我没那么着急用它。而且我之前另一篇文章投过一次这个杂志,也是经历和这次一模一样,由于不服气申诉了,后来重新审稿最终接收。这次被拒不想在申诉了,也心累,可能是因为人家升区了吧。<br>27 Dec 2022 Article rejected by Specialty Chief<br>22 Nov 2022 Review of Review Editor 1 finalized<br>21 Nov 2022 Review of Review Editor 3 finalized<br>14 Nov 2022 <br>Review of Review Editor 1 finalized<br>Corresponding Author re-submitted manuscript<br>You posted new comments<br>07 Nov 2022 <br>Interactive review forum activated<br>Review of Reviewer 3 is finalized<br>06 Sep 2022 Manuscript transferred to Frontiers in Endocrinology, section Cellular Endocrinology, research topic: None, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210722/ce07e4a5c3c140a6bb8f19209b4271a4/4355f14397864d6c8f0343fc06a29351.jpg, createdBy=614c5554341, createdName=ms1000000414896070, createdTime=Thu Jan 05 13:58:40 CST 2023, time=2023-01-05, status=1, ipAttribution=吉林省)]
[GetPortalCommentsPageByObjectIdResponse(id=2222724, encodeId=f35e2222e24b7, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:生殖内分泌<br>经验分享:朋友们,此期刊会进预警吗,浙大已经把frontiers全挂进预警了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c8b85315215, createdName=148975dam71暂无昵称, createdTime=Tue Aug 27 21:33:27 CST 2024, time=2024-08-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2109972, encodeId=b8e921099e22f, content=目前只有两个审稿人审稿,建议接受。现在状态变成The Associate Editor XX is evaluating any revisions made to the manuscript to take a final decision.<br>请问各位大佬还会继续邀请审稿人吗?这个状态会持续多久呀?谢谢你们<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1528458531, createdName=ms5000001329361729, createdTime=Thu Jan 12 16:16:25 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0<br>偏重的研究方向:糖尿病<br>经验分享:为什么我先被接受了,钱都交了,然后被拒了啊…………
This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208458, encodeId=124522084581c, content=请问这个期刊申请减免版面费的话成功率高么?会不会影响文章录用?通常文章什么状态的时候申请?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=我要毕业2024, createdTime=Wed Jun 05 15:54:27 CST 2024, time=2024-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198626, encodeId=15f5219862674, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:生殖医学<br>经验分享:15 Apr 2024 Article accepted for publication.<br>10 Apr 2024 Review of Review Editor 3 finalized.<br>04 Apr 2024 You posted new comments. Reviewer 3 posted new comments.<br>28 Mar 2024 Corresponding Author Chen Wang re-submitted manuscript.<br>14 Mar 2024 Interactive review forum activated.<br>25 Jan 2024 Review of Reviewer 1 is finalized.<br>23 Nov 2023 Corresponding Author Chen Wang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed3c2532598, createdName=125051b5m55(暂无昵称), createdTime=Mon Apr 15 15:36:02 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2165820, encodeId=716c2165820b0, content=感觉最近有点慢啊,卡在Editorial Assignment半个月了,丝毫没有动静,编辑们都去休假了吗?也还没到圣诞节吧..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230220/b6e40eea2fa5422ea67ef0e7c3b2e44b/808d8afa8f4d42fea20d07f572948bcf.jpg, createdBy=f8553109256, createdName=791313987, createdTime=Mon Oct 30 23:31:00 CST 2023, time=2023-10-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2179419, encodeId=74f721e94197a, content=偏重的研究方向:甲状腺癌<br>经验分享:现在cancer endocrinology板块的编辑是不是很忙,俩礼拜了还没分配编辑,还是内容不好,所以没有编辑愿意接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230712/7b1f2dc9a324479e9877047bc3d85ecd/b95cd487c3e24b4d8bfa2fc6ab30880c.jpg, createdBy=aed48754576, createdName=发大文章带我一个二十作吧, createdTime=Fri Jan 05 14:38:11 CST 2024, time=2024-01-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2131250, encodeId=976c213125070, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向:内分泌<br>经验分享:本人作为客座编辑在frontiers endocrinology(IF6.0)期刊开了一个主题为“Dysregulation of Metabolism and Associated Genes in Tumor Initiation, Development and Resistance to Radiotherapy and Immunotherapy”的专刊,现在已经开放投稿。如果大家有主题相关的稿件,欢迎大家积极投稿。投稿完成后,我会第一时间处理稿件并择优选择你们投稿时推荐的审稿专家,提升稿件处理流程和接收速度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 22:48:06 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2167281, encodeId=c94f216e28178, content=偏重的研究方向:癌症;Endocrinology<br>经验分享:投稿花了一个多月分配编辑,分配后邀请两个审稿人提交报告1个月,然后一直没动静,等了一个多月没有变化。这期刊也太不靠谱了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65ab5425857, createdName=Doctorfan, createdTime=Tue Nov 07 22:03:52 CST 2023, time=2023-11-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2108928, encodeId=aef1210892807, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向:糖尿病并发症<br>经验分享:给大家分享我的投稿经历,综述文章(也是从别的杂志转投过来的),找审稿人用了很长时间,期间还发邮件让我推荐最多十位审稿人,最终我的文章找到三个审稿人(有一人退出审稿),两个审稿人(Reviewer1有5个问题,Reviewer3有8个问题)提的问题自认为并不复杂,基本是语言需要润色,表格需要合并,摘要和讨论部分需要精细一下等。给了一周时间修改,我进行润色并仔细回答问题,11月14号按时投回。之前投内分泌前言的经验是投回很快就告诉接收。结果我等到12月27号收到拒稿,理由是This manuscript does not fulfill the standards established for the journal to be considered for publication. The overall judgement of the reviewers and handling editor is that the authors couldn't satisfy the concerns after during the review process. also, A lack of novelty exists.我就想说,你的理由真是服,送审之前想什么呢?将近4个月时间打水漂。。。。。。好在我没那么着急用它。而且我之前另一篇文章投过一次这个杂志,也是经历和这次一模一样,由于不服气申诉了,后来重新审稿最终接收。这次被拒不想在申诉了,也心累,可能是因为人家升区了吧。<br>27 Dec 2022 Article rejected by Specialty Chief<br>22 Nov 2022 Review of Review Editor 1 finalized<br>21 Nov 2022 Review of Review Editor 3 finalized<br>14 Nov 2022 <br>Review of Review Editor 1 finalized<br>Corresponding Author re-submitted manuscript<br>You posted new comments<br>07 Nov 2022 <br>Interactive review forum activated<br>Review of Reviewer 3 is finalized<br>06 Sep 2022 Manuscript transferred to Frontiers in Endocrinology, section Cellular Endocrinology, research topic: None, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210722/ce07e4a5c3c140a6bb8f19209b4271a4/4355f14397864d6c8f0343fc06a29351.jpg, createdBy=614c5554341, createdName=ms1000000414896070, createdTime=Thu Jan 05 13:58:40 CST 2023, time=2023-01-05, status=1, ipAttribution=吉林省)]
审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向:内分泌 经验分享:本人作为客座编辑在frontiers endocrinology(IF6.0)期刊开了一个主题为“Dysregulation of Metabolism and Associated Genes in Tumor Initiation, Development and Resistance to Radiotherapy and Immunotherapy”的专刊,现在已经开放投稿。如果大家有主题相关的稿件,欢迎大家积极投稿。投稿完成后,我会第一时间处理稿件并择优选择你们投稿时推荐的审稿专家,提升稿件处理流程和接收速度。
[GetPortalCommentsPageByObjectIdResponse(id=2222724, encodeId=f35e2222e24b7, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:生殖内分泌<br>经验分享:朋友们,此期刊会进预警吗,浙大已经把frontiers全挂进预警了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c8b85315215, createdName=148975dam71暂无昵称, createdTime=Tue Aug 27 21:33:27 CST 2024, time=2024-08-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2109972, encodeId=b8e921099e22f, content=目前只有两个审稿人审稿,建议接受。现在状态变成The Associate Editor XX is evaluating any revisions made to the manuscript to take a final decision.<br>请问各位大佬还会继续邀请审稿人吗?这个状态会持续多久呀?谢谢你们<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1528458531, createdName=ms5000001329361729, createdTime=Thu Jan 12 16:16:25 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0<br>偏重的研究方向:糖尿病<br>经验分享:为什么我先被接受了,钱都交了,然后被拒了啊…………
This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208458, encodeId=124522084581c, content=请问这个期刊申请减免版面费的话成功率高么?会不会影响文章录用?通常文章什么状态的时候申请?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=我要毕业2024, createdTime=Wed Jun 05 15:54:27 CST 2024, time=2024-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198626, encodeId=15f5219862674, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:生殖医学<br>经验分享:15 Apr 2024 Article accepted for publication.<br>10 Apr 2024 Review of Review Editor 3 finalized.<br>04 Apr 2024 You posted new comments. Reviewer 3 posted new comments.<br>28 Mar 2024 Corresponding Author Chen Wang re-submitted manuscript.<br>14 Mar 2024 Interactive review forum activated.<br>25 Jan 2024 Review of Reviewer 1 is finalized.<br>23 Nov 2023 Corresponding Author Chen Wang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed3c2532598, createdName=125051b5m55(暂无昵称), createdTime=Mon Apr 15 15:36:02 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2165820, encodeId=716c2165820b0, content=感觉最近有点慢啊,卡在Editorial Assignment半个月了,丝毫没有动静,编辑们都去休假了吗?也还没到圣诞节吧..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230220/b6e40eea2fa5422ea67ef0e7c3b2e44b/808d8afa8f4d42fea20d07f572948bcf.jpg, createdBy=f8553109256, createdName=791313987, createdTime=Mon Oct 30 23:31:00 CST 2023, time=2023-10-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2179419, encodeId=74f721e94197a, content=偏重的研究方向:甲状腺癌<br>经验分享:现在cancer endocrinology板块的编辑是不是很忙,俩礼拜了还没分配编辑,还是内容不好,所以没有编辑愿意接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230712/7b1f2dc9a324479e9877047bc3d85ecd/b95cd487c3e24b4d8bfa2fc6ab30880c.jpg, createdBy=aed48754576, createdName=发大文章带我一个二十作吧, createdTime=Fri Jan 05 14:38:11 CST 2024, time=2024-01-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2131250, encodeId=976c213125070, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向:内分泌<br>经验分享:本人作为客座编辑在frontiers endocrinology(IF6.0)期刊开了一个主题为“Dysregulation of Metabolism and Associated Genes in Tumor Initiation, Development and Resistance to Radiotherapy and Immunotherapy”的专刊,现在已经开放投稿。如果大家有主题相关的稿件,欢迎大家积极投稿。投稿完成后,我会第一时间处理稿件并择优选择你们投稿时推荐的审稿专家,提升稿件处理流程和接收速度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 22:48:06 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2167281, encodeId=c94f216e28178, content=偏重的研究方向:癌症;Endocrinology<br>经验分享:投稿花了一个多月分配编辑,分配后邀请两个审稿人提交报告1个月,然后一直没动静,等了一个多月没有变化。这期刊也太不靠谱了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65ab5425857, createdName=Doctorfan, createdTime=Tue Nov 07 22:03:52 CST 2023, time=2023-11-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2108928, encodeId=aef1210892807, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向:糖尿病并发症<br>经验分享:给大家分享我的投稿经历,综述文章(也是从别的杂志转投过来的),找审稿人用了很长时间,期间还发邮件让我推荐最多十位审稿人,最终我的文章找到三个审稿人(有一人退出审稿),两个审稿人(Reviewer1有5个问题,Reviewer3有8个问题)提的问题自认为并不复杂,基本是语言需要润色,表格需要合并,摘要和讨论部分需要精细一下等。给了一周时间修改,我进行润色并仔细回答问题,11月14号按时投回。之前投内分泌前言的经验是投回很快就告诉接收。结果我等到12月27号收到拒稿,理由是This manuscript does not fulfill the standards established for the journal to be considered for publication. The overall judgement of the reviewers and handling editor is that the authors couldn't satisfy the concerns after during the review process. also, A lack of novelty exists.我就想说,你的理由真是服,送审之前想什么呢?将近4个月时间打水漂。。。。。。好在我没那么着急用它。而且我之前另一篇文章投过一次这个杂志,也是经历和这次一模一样,由于不服气申诉了,后来重新审稿最终接收。这次被拒不想在申诉了,也心累,可能是因为人家升区了吧。<br>27 Dec 2022 Article rejected by Specialty Chief<br>22 Nov 2022 Review of Review Editor 1 finalized<br>21 Nov 2022 Review of Review Editor 3 finalized<br>14 Nov 2022 <br>Review of Review Editor 1 finalized<br>Corresponding Author re-submitted manuscript<br>You posted new comments<br>07 Nov 2022 <br>Interactive review forum activated<br>Review of Reviewer 3 is finalized<br>06 Sep 2022 Manuscript transferred to Frontiers in Endocrinology, section Cellular Endocrinology, research topic: None, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210722/ce07e4a5c3c140a6bb8f19209b4271a4/4355f14397864d6c8f0343fc06a29351.jpg, createdBy=614c5554341, createdName=ms1000000414896070, createdTime=Thu Jan 05 13:58:40 CST 2023, time=2023-01-05, status=1, ipAttribution=吉林省)]
[GetPortalCommentsPageByObjectIdResponse(id=2222724, encodeId=f35e2222e24b7, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:生殖内分泌<br>经验分享:朋友们,此期刊会进预警吗,浙大已经把frontiers全挂进预警了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c8b85315215, createdName=148975dam71暂无昵称, createdTime=Tue Aug 27 21:33:27 CST 2024, time=2024-08-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2109972, encodeId=b8e921099e22f, content=目前只有两个审稿人审稿,建议接受。现在状态变成The Associate Editor XX is evaluating any revisions made to the manuscript to take a final decision.<br>请问各位大佬还会继续邀请审稿人吗?这个状态会持续多久呀?谢谢你们<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1528458531, createdName=ms5000001329361729, createdTime=Thu Jan 12 16:16:25 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0<br>偏重的研究方向:糖尿病<br>经验分享:为什么我先被接受了,钱都交了,然后被拒了啊…………
This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208458, encodeId=124522084581c, content=请问这个期刊申请减免版面费的话成功率高么?会不会影响文章录用?通常文章什么状态的时候申请?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=我要毕业2024, createdTime=Wed Jun 05 15:54:27 CST 2024, time=2024-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198626, encodeId=15f5219862674, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:生殖医学<br>经验分享:15 Apr 2024 Article accepted for publication.<br>10 Apr 2024 Review of Review Editor 3 finalized.<br>04 Apr 2024 You posted new comments. Reviewer 3 posted new comments.<br>28 Mar 2024 Corresponding Author Chen Wang re-submitted manuscript.<br>14 Mar 2024 Interactive review forum activated.<br>25 Jan 2024 Review of Reviewer 1 is finalized.<br>23 Nov 2023 Corresponding Author Chen Wang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed3c2532598, createdName=125051b5m55(暂无昵称), createdTime=Mon Apr 15 15:36:02 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2165820, encodeId=716c2165820b0, content=感觉最近有点慢啊,卡在Editorial Assignment半个月了,丝毫没有动静,编辑们都去休假了吗?也还没到圣诞节吧..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230220/b6e40eea2fa5422ea67ef0e7c3b2e44b/808d8afa8f4d42fea20d07f572948bcf.jpg, createdBy=f8553109256, createdName=791313987, createdTime=Mon Oct 30 23:31:00 CST 2023, time=2023-10-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2179419, encodeId=74f721e94197a, content=偏重的研究方向:甲状腺癌<br>经验分享:现在cancer endocrinology板块的编辑是不是很忙,俩礼拜了还没分配编辑,还是内容不好,所以没有编辑愿意接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230712/7b1f2dc9a324479e9877047bc3d85ecd/b95cd487c3e24b4d8bfa2fc6ab30880c.jpg, createdBy=aed48754576, createdName=发大文章带我一个二十作吧, createdTime=Fri Jan 05 14:38:11 CST 2024, time=2024-01-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2131250, encodeId=976c213125070, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向:内分泌<br>经验分享:本人作为客座编辑在frontiers endocrinology(IF6.0)期刊开了一个主题为“Dysregulation of Metabolism and Associated Genes in Tumor Initiation, Development and Resistance to Radiotherapy and Immunotherapy”的专刊,现在已经开放投稿。如果大家有主题相关的稿件,欢迎大家积极投稿。投稿完成后,我会第一时间处理稿件并择优选择你们投稿时推荐的审稿专家,提升稿件处理流程和接收速度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 22:48:06 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2167281, encodeId=c94f216e28178, content=偏重的研究方向:癌症;Endocrinology<br>经验分享:投稿花了一个多月分配编辑,分配后邀请两个审稿人提交报告1个月,然后一直没动静,等了一个多月没有变化。这期刊也太不靠谱了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65ab5425857, createdName=Doctorfan, createdTime=Tue Nov 07 22:03:52 CST 2023, time=2023-11-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2108928, encodeId=aef1210892807, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向:糖尿病并发症<br>经验分享:给大家分享我的投稿经历,综述文章(也是从别的杂志转投过来的),找审稿人用了很长时间,期间还发邮件让我推荐最多十位审稿人,最终我的文章找到三个审稿人(有一人退出审稿),两个审稿人(Reviewer1有5个问题,Reviewer3有8个问题)提的问题自认为并不复杂,基本是语言需要润色,表格需要合并,摘要和讨论部分需要精细一下等。给了一周时间修改,我进行润色并仔细回答问题,11月14号按时投回。之前投内分泌前言的经验是投回很快就告诉接收。结果我等到12月27号收到拒稿,理由是This manuscript does not fulfill the standards established for the journal to be considered for publication. The overall judgement of the reviewers and handling editor is that the authors couldn't satisfy the concerns after during the review process. also, A lack of novelty exists.我就想说,你的理由真是服,送审之前想什么呢?将近4个月时间打水漂。。。。。。好在我没那么着急用它。而且我之前另一篇文章投过一次这个杂志,也是经历和这次一模一样,由于不服气申诉了,后来重新审稿最终接收。这次被拒不想在申诉了,也心累,可能是因为人家升区了吧。<br>27 Dec 2022 Article rejected by Specialty Chief<br>22 Nov 2022 Review of Review Editor 1 finalized<br>21 Nov 2022 Review of Review Editor 3 finalized<br>14 Nov 2022 <br>Review of Review Editor 1 finalized<br>Corresponding Author re-submitted manuscript<br>You posted new comments<br>07 Nov 2022 <br>Interactive review forum activated<br>Review of Reviewer 3 is finalized<br>06 Sep 2022 Manuscript transferred to Frontiers in Endocrinology, section Cellular Endocrinology, research topic: None, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210722/ce07e4a5c3c140a6bb8f19209b4271a4/4355f14397864d6c8f0343fc06a29351.jpg, createdBy=614c5554341, createdName=ms1000000414896070, createdTime=Thu Jan 05 13:58:40 CST 2023, time=2023-01-05, status=1, ipAttribution=吉林省)]
审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向:糖尿病并发症 经验分享:给大家分享我的投稿经历,综述文章(也是从别的杂志转投过来的),找审稿人用了很长时间,期间还发邮件让我推荐最多十位审稿人,最终我的文章找到三个审稿人(有一人退出审稿),两个审稿人(Reviewer1有5个问题,Reviewer3有8个问题)提的问题自认为并不复杂,基本是语言需要润色,表格需要合并,摘要和讨论部分需要精细一下等。给了一周时间修改,我进行润色并仔细回答问题,11月14号按时投回。之前投内分泌前言的经验是投回很快就告诉接收。结果我等到12月27号收到拒稿,理由是This manuscript does not fulfill the standards established for the journal to be considered for publication. The overall judgement of the reviewers and handling editor is that the authors couldn't satisfy the concerns after during the review process. also, A lack of novelty exists.我就想说,你的理由真是服,送审之前想什么呢?将近4个月时间打水漂。。。。。。好在我没那么着急用它。而且我之前另一篇文章投过一次这个杂志,也是经历和这次一模一样,由于不服气申诉了,后来重新审稿最终接收。这次被拒不想在申诉了,也心累,可能是因为人家升区了吧。 27 Dec 2022 Article rejected by Specialty Chief 22 Nov 2022 Review of Review Editor 1 finalized 21 Nov 2022 Review of Review Editor 3 finalized 14 Nov 2022 Review of Review Editor 1 finalized Corresponding Author re-submitted manuscript You posted new comments 07 Nov 2022 Interactive review forum activated Review of Reviewer 3 is finalized 06 Sep 2022 Manuscript transferred to Frontiers in Endocrinology, section Cellular Endocrinology, research topic: None
审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向:生殖内分泌
经验分享:朋友们,此期刊会进预警吗,浙大已经把frontiers全挂进预警了
34
目前只有两个审稿人审稿,建议接受。现在状态变成The Associate Editor XX is evaluating any revisions made to the manuscript to take a final decision.
请问各位大佬还会继续邀请审稿人吗?这个状态会持续多久呀?谢谢你们
251
审稿速度:1.0
偏重的研究方向:糖尿病
经验分享:为什么我先被接受了,钱都交了,然后被拒了啊………… This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final.
242
请问这个期刊申请减免版面费的话成功率高么?会不会影响文章录用?通常文章什么状态的时候申请?
113
审稿速度:6.0 | 投稿命中率:75.0
偏重的研究方向:生殖医学
经验分享:15 Apr 2024 Article accepted for publication.
10 Apr 2024 Review of Review Editor 3 finalized.
04 Apr 2024 You posted new comments. Reviewer 3 posted new comments.
28 Mar 2024 Corresponding Author Chen Wang re-submitted manuscript.
14 Mar 2024 Interactive review forum activated.
25 Jan 2024 Review of Reviewer 1 is finalized.
23 Nov 2023 Corresponding Author Chen Wang submitted manuscript.
142
感觉最近有点慢啊,卡在Editorial Assignment半个月了,丝毫没有动静,编辑们都去休假了吗?也还没到圣诞节吧...
181
偏重的研究方向:甲状腺癌
经验分享:现在cancer endocrinology板块的编辑是不是很忙,俩礼拜了还没分配编辑,还是内容不好,所以没有编辑愿意接
195
审稿速度:2.0 | 投稿命中率:95.0
偏重的研究方向:内分泌
经验分享:本人作为客座编辑在frontiers endocrinology(IF6.0)期刊开了一个主题为“Dysregulation of Metabolism and Associated Genes in Tumor Initiation, Development and Resistance to Radiotherapy and Immunotherapy”的专刊,现在已经开放投稿。如果大家有主题相关的稿件,欢迎大家积极投稿。投稿完成后,我会第一时间处理稿件并择优选择你们投稿时推荐的审稿专家,提升稿件处理流程和接收速度。
244
偏重的研究方向:癌症;Endocrinology
经验分享:投稿花了一个多月分配编辑,分配后邀请两个审稿人提交报告1个月,然后一直没动静,等了一个多月没有变化。这期刊也太不靠谱了
212
审稿速度:6.0 | 投稿命中率:25.0
偏重的研究方向:糖尿病并发症
经验分享:给大家分享我的投稿经历,综述文章(也是从别的杂志转投过来的),找审稿人用了很长时间,期间还发邮件让我推荐最多十位审稿人,最终我的文章找到三个审稿人(有一人退出审稿),两个审稿人(Reviewer1有5个问题,Reviewer3有8个问题)提的问题自认为并不复杂,基本是语言需要润色,表格需要合并,摘要和讨论部分需要精细一下等。给了一周时间修改,我进行润色并仔细回答问题,11月14号按时投回。之前投内分泌前言的经验是投回很快就告诉接收。结果我等到12月27号收到拒稿,理由是This manuscript does not fulfill the standards established for the journal to be considered for publication. The overall judgement of the reviewers and handling editor is that the authors couldn't satisfy the concerns after during the review process. also, A lack of novelty exists.我就想说,你的理由真是服,送审之前想什么呢?将近4个月时间打水漂。。。。。。好在我没那么着急用它。而且我之前另一篇文章投过一次这个杂志,也是经历和这次一模一样,由于不服气申诉了,后来重新审稿最终接收。这次被拒不想在申诉了,也心累,可能是因为人家升区了吧。
27 Dec 2022 Article rejected by Specialty Chief
22 Nov 2022 Review of Review Editor 1 finalized
21 Nov 2022 Review of Review Editor 3 finalized
14 Nov 2022
Review of Review Editor 1 finalized
Corresponding Author re-submitted manuscript
You posted new comments
07 Nov 2022
Interactive review forum activated
Review of Reviewer 3 is finalized
06 Sep 2022 Manuscript transferred to Frontiers in Endocrinology, section Cellular Endocrinology, research topic: None
266